Successful treatment of patients with von Willebrand disease using a high-purity double-virus inactivated factor VIII/von Willebrand factor concentrate (Immunate).
Fourteen patients with different types of von Willebrand disease (vWD) having acute bleeds or elective surgery were treated with Immunate(sound recording copyright sign), a double-virus inactivated factor VIII/von Willebrand factor (FVIII/vWF) concentrate. The concentrate was applied as a bolus or via continuous infusion. FVIII activity (FVIIIc), vWF antigen (vWF:Ag), ristocetin cofactor activity (vWF:RCo), collagen binding activity (vWF:CB), activated partial thromboplastin time (aPTT), and von Willebrand multimers (vW-multimers) were monitored for 48 hours. Pharmacokinetic analyses were performed. The clinical efficacy was rated excellent or good. Bleeding complications occurred in 3 patients due to an additional FXIII deficiency in one patient, to a surgically induced bleed in another patient, and a rather short substitution period in the third patient. There were no serious adverse experiences. One patient showed a phlebitic reaction at the site of venous access after more than 100 hours of continuous infusion, requiring a change to application via bolus.
Auerswald
Günter
G
Prof. Hess Kinderklinik, St.-Jürgen-Strasse 1, Bremen, Germany.
Eberspächer
Bruno
B
Engl
Werner
W
Güthner
Christiane
C
Koksch
Marie
M
Kreuz
Wolfhart
W
Nimtz
Antje
A
Pindur
Gerhard
G
Scheel
Horst
H
Schreiber
Jörg D
JD
Siekmann
Jürgen
J
Turecek
Peter L
PL
Wolf
Hans-Heinrich
HH
D019411:Clinical Laboratory Techniques; D019281:Dimerization; D004338:Drug Combinations; D016903:Drug Monitoring / Q000379:methods; D005169:Factor VIII / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005260:Female; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D008297:Male; D019990:Perioperative Care / Q000379:methods; D013242:Sterilization; D016896:Treatment Outcome; D014842:von Willebrand Diseases / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D014841:von Willebrand Factor / Q000008:administration & dosage* / Q000493:pharmacokinetics
D004338:Drug Combinations; D014841:von Willebrand Factor; D005169:Factor VIII